{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T15:49:43Z","timestamp":1775317783942,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Huanghe Talented Scholar Grant of Wuhan City","award":["1010\/06850002"],"award-info":[{"award-number":["1010\/06850002"]}]},{"name":"Jianghan University collaborative Innovation grant","award":["3010\/03100070"],"award-info":[{"award-number":["3010\/03100070"]}]},{"name":"Jianghan University Talent Training Grant","award":["3015\/06210046"],"award-info":[{"award-number":["3015\/06210046"]}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81602642"],"award-info":[{"award-number":["81602642"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The zinc complex of 3,5-di-tert-butyl salicylate (Zn{[CH<jats:sub>3<\/jats:sub>)<jats:sub>3<\/jats:sub>C]<jats:sub>2<\/jats:sub>Sal}<jats:sub>2<\/jats:sub><jats:sup>2\u2212<\/jats:sup>) is a zinc ion chelate of salicylate. In this study, we found that this compound inhibits viability, invasion, and migration and induces apoptosis in triple-negative breast cancer 4T1 cells. RNA-seq showed that the expression of 17 genes was upregulated and 26 genes were downregulated significantly by Zn{[CH<jats:sub>3<\/jats:sub>)<jats:sub>3<\/jats:sub>C]<jats:sub>2<\/jats:sub>Sal}<jats:sub>2<\/jats:sub><jats:sup>2\u2212<\/jats:sup> treatment. Further GO and KEGG analysis showed that the activity of Zn{[CH<jats:sub>3<\/jats:sub>)<jats:sub>3<\/jats:sub>C]<jats:sub>2<\/jats:sub>Sal}<jats:sub>2<\/jats:sub><jats:sup>2\u2212<\/jats:sup> against triple-negative breast cancer cells may be involved in the JAK-STAT3, HIF-1, and TNF signaling pathways. The expression of key genes was verified by RT\u2013PCR. The phosphorylation of STAT3 and its upstream SRC decreased drastically upon Zn{[CH<jats:sub>3<\/jats:sub>)<jats:sub>3<\/jats:sub>C]<jats:sub>2<\/jats:sub>Sal}<jats:sub>2<\/jats:sub><jats:sup>2\u2212<\/jats:sup> treatment, as demonstrated by western blot. Our results indicate that Zn{[CH<jats:sub>3<\/jats:sub>)<jats:sub>3<\/jats:sub>C]<jats:sub>2<\/jats:sub>Sal}<jats:sub>2<\/jats:sub><jats:sup>2\u2212<\/jats:sup> inhibits the activity of TNBC cells by downregulating the STAT3 signaling through the SRC pathway.<\/jats:p>","DOI":"10.1038\/s41598-022-08704-0","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T15:03:48Z","timestamp":1647443028000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Zinc complex of 3,5-di-tert-butyl salicylate inhibits viability, migration, and invasion in triple-negative breast cancer cells"],"prefix":"10.1038","volume":"12","author":[{"given":"Heng","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Limei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zixin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"8704_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ejso.2020.09.022","volume":"47","author":"Y Jauhari","year":"2021","unstructured":"Jauhari, Y. et al. The influence of age, comorbidity and frailty on treatment with surgery and systemic therapy in older women with operable triple negative breast cancer (TNBC) in England: A population-based cohort study. Eur. J. Surg. Oncol. 47, 251\u2013260. https:\/\/doi.org\/10.1016\/j.ejso.2020.09.022 (2021).","journal-title":"Eur. J. Surg. Oncol."},{"key":"8704_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.31557\/APJCP.2021.22.1.151","volume":"22","author":"RI Jenie","year":"2021","unstructured":"Jenie, R. I. et al. The evaluation of cytotoxic properties from CCB-2 sugar complexes against TNBC and non-TNBC cells. Asian Pac. J. Cancer Prev. 22, 151\u2013155. https:\/\/doi.org\/10.31557\/APJCP.2021.22.1.151 (2021).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"8704_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1038\/s41571-020-00465-x","volume":"18","author":"D Killock","year":"2021","unstructured":"Killock, D. Pembrolizumab can delay progression of TNBC. Nat. Rev. Clin. Oncol. 18, 1817\u20131828. https:\/\/doi.org\/10.1038\/s41571-020-00465-x (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"8704_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.yexcr.2018.01.018","volume":"363","author":"MP Moreira","year":"2018","unstructured":"Moreira, M. P., Braga, L. D., Cassali, G. D. & Silva, L. M. STAT3 as a promising chemoresistance biomarker associated with the CD44(+\/high)\/CD24(\u2212\/low)\/ALDH(+) BCSCs-like subset of the triple-negative breast cancer (TNBC) cell line. Exp. Cell Res. 363, 283\u2013290. https:\/\/doi.org\/10.1016\/j.yexcr.2018.01.018 (2018).","journal-title":"Exp. Cell Res."},{"key":"8704_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188521","volume":"1875","author":"J Jin","year":"2021","unstructured":"Jin, J., Tao, Z., Cao, J., Li, T. & Hu, X. DNA damage response inhibitors: An avenue for TNBC treatment. Biochim. Biophys. Acta Rev Cancer 1875, 188521. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188521 (2021).","journal-title":"Biochim. Biophys. Acta Rev Cancer"},{"key":"8704_CR6","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3390\/cancers12040916","volume":"12","author":"E Vagia","year":"2020","unstructured":"Vagia, E., Mahalingam, D. & Cristofanilli, M. The landscape of targeted therapies in TNBC. Cancers (Basel) 12, 916\u2013941. https:\/\/doi.org\/10.3390\/cancers12040916 (2020).","journal-title":"Cancers (Basel)"},{"key":"8704_CR7","doi-asserted-by":"publisher","first-page":"100031","DOI":"10.1016\/j.mbplus.2020.100031","volume":"6\u20137","author":"TT Karalis","year":"2020","unstructured":"Karalis, T. T. et al. Salicylate suppresses the oncogenic hyaluronan network in metastatic breast cancer cells. Matrix Biol. Plus 6\u20137, 100031. https:\/\/doi.org\/10.1016\/j.mbplus.2020.100031 (2020).","journal-title":"Matrix Biol. Plus"},{"key":"8704_CR8","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.2337\/diabetes.51.6.1772","volume":"51","author":"PO Tran","year":"2002","unstructured":"Tran, P. O., Gleason, C. E. & Robertson, R. P. Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function. Diabetes 51, 1772\u20131778. https:\/\/doi.org\/10.2337\/diabetes.51.6.1772 (2002).","journal-title":"Diabetes"},{"key":"8704_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1042\/BJ20150122","volume":"469","author":"AJ O'Brien","year":"2015","unstructured":"O\u2019Brien, A. J. et al. Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis. Biochem. J. 469, 177\u2013187. https:\/\/doi.org\/10.1042\/BJ20150122 (2015).","journal-title":"Biochem. J."},{"key":"8704_CR10","doi-asserted-by":"publisher","first-page":"115359","DOI":"10.1016\/j.taap.2020.115359","volume":"410","author":"JNR Gnanaprakasam","year":"2021","unstructured":"Gnanaprakasam, J. N. R., Lopez-Banuelos, L. & Vega, L. Anacardic 6-pentadecyl salicylic acid induces apoptosis in breast cancer tumor cells, immunostimulation in the host and decreases blood toxic effects of taxol in an animal model. Toxicol. Appl. Pharmacol. 410, 115359. https:\/\/doi.org\/10.1016\/j.taap.2020.115359 (2021).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"8704_CR11","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1046\/j.1538-7836.2003.00446.x","volume":"1","author":"MI Shtivelband","year":"2003","unstructured":"Shtivelband, M. I., Juneja, H. S., Lee, S. & Wu, K. K. Aspirin and salicylate inhibit colon cancer medium- and VEGF-induced endothelial tube formation: Correlation with suppression of cyclooxygenase-2 expression. J. Thromb. Haemost. 1, 2225\u20132233. https:\/\/doi.org\/10.1046\/j.1538-7836.2003.00446.x (2003).","journal-title":"J. Thromb. Haemost."},{"key":"8704_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.clbc.2017.03.015","volume":"17","author":"J Madunic","year":"2017","unstructured":"Madunic, J. et al. Sodium salicylate inhibits urokinase activity in MDA MB-231 breast cancer cells. Clin. Breast Cancer 17, 629\u2013637. https:\/\/doi.org\/10.1016\/j.clbc.2017.03.015 (2017).","journal-title":"Clin. Breast Cancer"},{"key":"8704_CR13","doi-asserted-by":"publisher","first-page":"18928","DOI":"10.1002\/jcp.28533","volume":"234","author":"L Lin","year":"2019","unstructured":"Lin, L., Li, G., Zhang, W., Wang, Y. L. & Yang, H. Low-dose aspirin reduces hypoxia-induced sFlt1 release via the JNK\/AP-1 pathway in human trophoblast and endothelial cells. J. Cell Physiol. 234, 18928\u201318941. https:\/\/doi.org\/10.1002\/jcp.28533 (2019).","journal-title":"J. Cell Physiol."},{"key":"8704_CR14","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.2174\/092986707780831041","volume":"14","author":"JR Sorenson","year":"2007","unstructured":"Sorenson, J. R. & Wangila, G. W. Co-treatment with copper compounds dramatically decreases toxicities observed with cisplatin cancer therapy and the anticancer efficacy of some copper chelates supports the conclusion that copper chelate therapy may be markedly more effective and less toxic than cisplatin therapy. Curr. Med. Chem. 14, 1499\u20131503. https:\/\/doi.org\/10.2174\/092986707780831041 (2007).","journal-title":"Curr. Med. Chem."},{"key":"8704_CR15","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1021\/jm201041d","volume":"55","author":"M O'Connor","year":"2012","unstructured":"O\u2019Connor, M. et al. Copper(II) complexes of salicylic acid combining superoxide dismutase mimetic properties with DNA binding and cleaving capabilities display promising chemotherapeutic potential with fast acting in vitro cytotoxicity against cisplatin sensitive and resistant cancer cell lines. J. Med. Chem. 55, 1957\u20131968. https:\/\/doi.org\/10.1021\/jm201041d (2012).","journal-title":"J. Med. Chem."},{"key":"8704_CR16","doi-asserted-by":"publisher","first-page":"29823","DOI":"10.18632\/oncotarget.16161","volume":"8","author":"L Fan","year":"2017","unstructured":"Fan, L. et al. Salicylate *Phenanthroline copper(II) complex induces apoptosis in triple-negative breast cancer cells. Oncotarget 8, 29823\u201329832. https:\/\/doi.org\/10.18632\/oncotarget.16161 (2017).","journal-title":"Oncotarget"},{"key":"8704_CR17","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3390\/cancers11050731","volume":"11","author":"PSY Chong","year":"2019","unstructured":"Chong, P. S. Y., Chng, W. J. & de Mel, S. STAT3: A promising therapeutic target in multiple myeloma. Cancers 11, 731. https:\/\/doi.org\/10.3390\/cancers11050731 (2019).","journal-title":"Cancers"},{"key":"8704_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0992-z","author":"XX Dai","year":"2018","unstructured":"Dai, X. X. et al. Osthole inhibits triple negative breast cancer cells by suppressing STAT3. J. Exp. Clin. Cancer Res. https:\/\/doi.org\/10.1186\/s13046-018-0992-z (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"8704_CR19","doi-asserted-by":"publisher","first-page":"e9281","DOI":"10.7717\/peerj.9281","volume":"8","author":"P Wang","year":"2020","unstructured":"Wang, P. et al. Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1\/NF-kappaB and ERK pathways. PeerJ 8, e9281. https:\/\/doi.org\/10.7717\/peerj.9281 (2020).","journal-title":"PeerJ"},{"key":"8704_CR20","doi-asserted-by":"publisher","first-page":"602817","DOI":"10.3389\/fonc.2020.602817","volume":"10","author":"J Xu","year":"2020","unstructured":"Xu, J., Koval, A. & Katanaev, V. L. Beyond TNBC: Repositioning of clofazimine against a broad range of Wnt-dependent cancers. Front. Oncol. 10, 602817. https:\/\/doi.org\/10.3389\/fonc.2020.602817 (2020).","journal-title":"Front. Oncol."},{"key":"8704_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cells9122619","author":"DC Rigiracciolo","year":"2020","unstructured":"Rigiracciolo, D. C. et al. Correction: Rigiracciolo, D.C., et al., IGF-1\/IGF-1R\/FAK\/YAP transduction signaling prompts growth effects in triple-negative breast cancer (TNBC) cells. Cells 2020, 9, 1010. Cells https:\/\/doi.org\/10.3390\/cells9122619 (2020).","journal-title":"Cells"},{"key":"8704_CR22","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1038\/sj.onc.1204349","volume":"20","author":"R Garcia","year":"2001","unstructured":"Garcia, R. et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20, 2499\u20132513. https:\/\/doi.org\/10.1038\/sj.onc.1204349 (2001).","journal-title":"Oncogene"},{"key":"8704_CR23","doi-asserted-by":"publisher","first-page":"20517","DOI":"10.18632\/oncotarget.15259","volume":"8","author":"JG Jackson","year":"2017","unstructured":"Jackson, J. G. & Lozano, G. TNBC invasion: Downstream of STAT3. Oncotarget 8, 20517\u201320518. https:\/\/doi.org\/10.18632\/oncotarget.15259 (2017).","journal-title":"Oncotarget"},{"key":"8704_CR24","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nrc3818","volume":"14","author":"H Yu","year":"2014","unstructured":"Yu, H., Lee, H., Herrmann, A., Buettner, R. & Jove, R. Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat. Rev. Cancer 14, 736\u2013746. https:\/\/doi.org\/10.1038\/nrc3818 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"8704_CR25","doi-asserted-by":"publisher","first-page":"40158","DOI":"10.18632\/oncotarget.5522","volume":"6","author":"MS Kim","year":"2015","unstructured":"Kim, M. S., Lee, W. S., Jeong, J., Kim, S. J. & Jin, W. Induction of metastatic potential by TrkB via activation of IL6\/JAK2\/STAT3 and PI3K\/AKT signaling in breast cancer. Oncotarget 6, 40158\u201340171. https:\/\/doi.org\/10.18632\/oncotarget.5522 (2015).","journal-title":"Oncotarget"},{"key":"8704_CR26","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.59809","author":"H Nishida","year":"2021","unstructured":"Nishida, H. et al. Methionine restriction breaks obligatory coupling of cell proliferation and death by an oncogene Src in Drosophila. Elife https:\/\/doi.org\/10.7554\/eLife.59809 (2021).","journal-title":"Elife"},{"key":"8704_CR27","doi-asserted-by":"publisher","first-page":"100261","DOI":"10.1016\/j.jbc.2021.100261","volume":"296","author":"T Chatterjee","year":"2021","unstructured":"Chatterjee, T. et al. Anti-GPR56 monoclonal antibody potentiates GPR56-mediated Src-Fak signaling to modulate cell adhesion. J. Biol. Chem. 296, 100261. https:\/\/doi.org\/10.1016\/j.jbc.2021.100261 (2021).","journal-title":"J. Biol. Chem."},{"key":"8704_CR28","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1128\/MCB.25.12.4826-4840.2005","volume":"25","author":"C Proietti","year":"2005","unstructured":"Proietti, C. et al. Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol. Cell Biol. 25, 4826\u20134840. https:\/\/doi.org\/10.1128\/MCB.25.12.4826-4840.2005 (2005).","journal-title":"Mol. Cell Biol."},{"key":"8704_CR29","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson, D. E., O\u2019Keefe, R. A. & Grandis, J. R. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15, 234\u2013248. https:\/\/doi.org\/10.1038\/nrclinonc.2018.8 (2018).","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08704-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08704-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08704-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T23:56:41Z","timestamp":1669334201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08704-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8704"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-08704-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]},"assertion":[{"value":"25 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4545"}}